Evaluating Cefiderocol in the Treatment of Multidrug | 合法藥品大搜索

由DRGiacobbe著作·2020·被引用4次—CefiderocolisanovelsiderophorecephalosporinactiveagainstGNB,includingstrainsofEnterobacteralesandnonfermentersthatexhibit ...

Infections due to multidrug-resistant Gram-negative bacteria (MDR-GNB), especially when carbapenem resistant, have been very difficult to manage in the past fifteen years, owing to the paucity of therapeutic options.1–5[1] Furthermore, available options such as polymyxins, aminoglycosides, and/or glycylcyclines, although certainly useful in presence or resistance to all other classes, have some disadvantages that clinicians would like to avoid, including nonnegligible toxicity and possible suboptimal pharmacokinetics in some sites of infection.6–8[2]

Some precious additions to the antibiotic armamentarium such as ceftazidime/avibactam, ceftolozane/tazobactam, meropenem/vaborbactam, and imipenem/relebactam have recently allowed to renew the availability of β-lactam antibiotics (that usually display good safety profiles and pharmacokinetics) for treating some MDR-GNB.9–12[3] However, some gaps still need to be filled, for example, restoring the activity of β-lactam...